Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9906255 | 0.76 | MCL1 (0.31) | — | |
| SCHEMBL4152740 | 0.75 | LMNA (0.43) | LMNAALOX15BLMPMP22MAPT | |
| SCHEMBL1267363 | 0.71 | — | — | |
| SCHEMBL1090931 | 0.69 | LMNA (0.38) | LMNAALOX15BLMPMP22MAPT | |
| SCHEMBL668141 | 0.67 | — | — | |
| SCHEMBL25917062 | 0.67 | LMNA (0.35) | LMNAALOX15BLMPMP22MAPT | |
| SCHEMBL22788847 | 0.67 | LMNA (0.30) | LMNAALOX15BLMPMP22MAPT | |
| SCHEMBL15128371 | 0.65 | LMNA (0.33) | LMNAALOX15BLMPMP22MAPT | |
| SCHEMBL11050625 | 0.65 | TSHR (0.42) | LMNAALOX15BLMPMP22MAPT | |
| SCHEMBL17550605 | 0.65 | LMNA (0.41) | LMNAALOX15BLMPMP22MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107686455-A | N-octadecyl ethylimidonate methyl ester and synthetic method thereof | 中国石油天然气股份有限公司 | 2018-02-13 | — | — | CN | disclosed |
| CN-107473985-A | N-hexadecyl ethylimido acid methyl ester and synthetic method thereof | 中国石油天然气股份有限公司 | 2017-12-15 | — | — | CN | disclosed |
| CN-107473984-A | N-tetradecyl ethylimidonate methyl ester and synthetic method thereof | 中国石油天然气股份有限公司 | 2017-12-15 | — | — | CN | disclosed |
| CN-107473983-A | N-dodecyl methyl ethylimidoate and synthetic method thereof | 中国石油天然气股份有限公司 | 2017-12-15 | — | — | CN | disclosed |
| US-9045484-B2 | Inhibitors of the BMP signaling pathway | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| EP-2265603-B1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | GEN HOSPITAL CORP (US) | 2014-05-07 | — | — | EP | disclosed |
| US-20140011805-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2014-01-09 | — | — | US | disclosed |
| US-8507501-B2 | Inhibitors of the BMP signaling pathway | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| EP-2265603-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | The General Hospital Corporation (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009114180-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE GENERAL HOSPITAL CORPORATION (US) | 2009-09-17 | — | — | WO | disclosed |
| EP-1332132-A2 | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES | Celltech R&D Limited (GB) | 2003-08-06 | — | — | EP | disclosed |
| EP-1286995-A1 | 2,7-NAPHTHYRIDINE DERIVATIVES | Celltech R&D Limited (GB) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001092256-A1 | 2,7-NAPHTHYRIDINE DERIVATIVES | CELLTECH R & D LIMITED (GB) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001079173-A2 | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES | CELLTECH R & D LIMITED (GB) | 2001-10-25 | — | — | WO | disclosed |
| EP-0827495-A4 | SUBSTITUTED-PENT-4-YNOIC ACIDS | SMITHKLINE BEECHAM CORP (US) | 1998-11-04 | — | — | EP | disclosed |
| EP-0827495-A1 | SUBSTITUTED-PENT-4-YNOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-03-11 | — | — | EP | disclosed |
| WO-1997003945-A1 | SUBSTITUTED-PENT-4-YNOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | BMP1, BMP2K, BMP2 | LMNA 1922/4885ALOX15 2494/4885BLM 3969/4885 |
| US-20140011805-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | BMP1, BMP2K, BMP2 | LMNA 1922/4885ALOX15 2494/4885BLM 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.